Compounds > pcf 39
Page last updated: 2024-10-15

pcf 39

Description

PCF 39: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135413509
CHEMBL ID319760
MeSH IDM0153686

Synonyms (16)

Synonym
CHEMBL319760
st-789
pcf-39
pcf 39
n2-(5-(hypoxanthin-9-yl)pentyloxycarbonyl)-l-arginine
l-arginine, n2-[[[5-(1,6-dihydro-6-oxo-9h-purin-9-yl)pentyl]oxy]carbonyl]-
104317-64-8
(2s)-5-guanidino-2-[5-(6-oxo-1h-purin-9-yl)pentoxycarbonylamino]pentanoic acid
(2s)-5-(diaminomethylideneamino)-2-[5-(6-oxo-3h-purin-9-yl)pentoxycarbonylamino]pentanoic acid
st 789
l-arginine, n2-(((5-(1,6-dihydro-6-oxo-9h-purin-9-yl)pentyl)oxy)carbonyl)-
n(2)-(5-(hypoxanthin-9-yl)pentyloxycarbonyl)arginine
DTXSID50146386
(s)-5-guanidino-2-((((5-(6-oxo-1h-purin-9(6h)-yl)pentyl)oxy)carbonyl)amino)pentanoic acid
cid 128533
PD161292

Pharmacokinetics

ExcerptReference
" A HPLC method validated for pharmacokinetic studies allowed the Authors to assay ST 789 concentration in plasma, urine and tissues."( Pharmacokinetic investigation of ST 789 in rats and mice.
Cardace, G; Mancinelli, A; Martelli, EA; Marzo, A, 1992)

Bioavailability

ExcerptReference
"5% of the drug given to be excreted in urine, this leading to conclude that this drug is poorly absorbed through the intestine wall."( Pharmacokinetic investigation of ST 789 in rats and mice.
Cardace, G; Mancinelli, A; Martelli, EA; Marzo, A, 1992)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID210444In vitro cytotoxic T-Lymphocyte (CTL) activity relative to interleukin 2 was obtained at a concentration of 10 e -7 M(++ represents 41 - 60% of interleukin 2)1997Journal of medicinal chemistry, Aug-29, Volume: 40, Issue:18
Synthesis and activity of 6-substituted purine linker amino acid immunostimulants.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (20)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (15.00)18.7374
1990's17 (85.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (95.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
caffeine
[no description available]		1.9710purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		5.38190arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
benzoin
[no description available]		1.9810benzoins;
secondary alpha-hydroxy ketone		EC 3.1.1.1 (carboxylesterase) inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.3820antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Acute Lymphoid Leukemia
[description not available]		01.9810
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		01.9810
Experimental Neoplasms
[description not available]		02.3820
Bacterial Disease
[description not available]		01.9810
Fungal Diseases
[description not available]		01.9810
Bacterial Infections
Infections by bacteria, general or unspecified.		01.9810
Mycoses
Diseases caused by FUNGI.		01.9810
Candida Infection
[description not available]		01.9710
Antibody Deficiency Syndrome
[description not available]		01.9710
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		01.9710
Immunologic Deficiency Syndromes
Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.		01.9710
Diabetes Mellitus, Adult-Onset
[description not available]		01.9710
Malignant Melanoma
[description not available]		01.9710
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		01.9710
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		01.9710
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		01.9710
Adenocarcinoma, Basal Cell
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		01.9710